BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28004113)

  • 41. Inhibition of p21 and Akt potentiates SU6656-induced caspase-independent cell death in FRO anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Horm Metab Res; 2013 Jun; 45(6):408-14. PubMed ID: 23386415
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Iodine induces apoptosis via regulating MAPKs-related p53, p21, and Bcl-xL in thyroid cancer cells.
    Liu XH; Chen GG; Vlantis AC; Tse GM; van Hasselt CA
    Mol Cell Endocrinol; 2010 May; 320(1-2):128-35. PubMed ID: 20138958
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
    Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
    Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The hsp70 inhibitor VER155008 induces paraptosis requiring de novo protein synthesis in anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Biochem Biophys Res Commun; 2014 Nov; 454(1):36-41. PubMed ID: 25450359
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CCAAT/Enhancer-binding protein-homologous protein sensitizes to SU5416 by modulating p21 and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Horm Metab Res; 2013 Jan; 45(1):9-14. PubMed ID: 22918703
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells.
    Yang X; Zhang N; Shi Z; Yang Z; Hu X
    Mol Med Rep; 2015 Apr; 11(4):2908-12. PubMed ID: 25501628
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.
    Xiao X; Ning L; Chen H
    Mol Cancer Ther; 2009 Feb; 8(2):350-6. PubMed ID: 19190121
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
    Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP
    Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
    Ishihara S; Onoda N; Noda S; Asano Y; Tauchi Y; Morisaki T; Kashiwagi S; Takashima T; Ohira M
    Int J Oncol; 2019 Nov; 55(5):1069-1076. PubMed ID: 31545405
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration.
    Chiappetta G; Valentino T; Vitiello M; Pasquinelli R; Monaco M; Palma G; Sepe R; Luciano A; Pallante P; Palmieri D; Aiello C; Rea D; Losito SN; Arra C; Fusco A; Fedele M
    Oncotarget; 2015 Mar; 6(7):5310-23. PubMed ID: 25595894
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
    Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
    Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model.
    Zhong WB; Tsai YC; Chin LH; Tseng JH; Tang LW; Horng S; Fan YC; Hsu SP
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29932104
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
    Iyer PC; Dadu R; Gule-Monroe M; Busaidy NL; Ferrarotto R; Habra MA; Zafereo M; Williams MD; Gunn GB; Grosu H; Skinner HD; Sturgis EM; Gross N; Cabanillas ME
    J Immunother Cancer; 2018 Jul; 6(1):68. PubMed ID: 29996921
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.
    von Roemeling CA; Copland JA
    Expert Opin Ther Targets; 2016; 20(2):159-66. PubMed ID: 26414044
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.
    Saltman B; Singh B; Hedvat CV; Wreesmann VB; Ghossein R
    Surgery; 2006 Dec; 140(6):899-905; discussion 905-6. PubMed ID: 17188136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nobiletin Alone or in Combination with Cisplatin Decreases the Viability of Anaplastic Thyroid Cancer Cell Lines.
    Sousa DP; Pojo M; Pinto AT; Leite V; Serra AT; Cavaco BM
    Nutr Cancer; 2020; 72(2):352-363. PubMed ID: 31287730
    [No Abstract]   [Full Text] [Related]  

  • 58. Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation.
    Jang S; Yu XM; Odorico S; Clark M; Jaskula-Sztul R; Schienebeck CM; Kupcho KR; Harrison AD; Winston-McPherson GN; Tang W; Chen H
    Cancer Gene Ther; 2015 Aug; 22(8):410-6. PubMed ID: 26251030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.
    Marlow LA; Bok I; Smallridge RC; Copland JA
    Endocr Relat Cancer; 2015 Oct; 22(5):777-92. PubMed ID: 26206775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ym155 Induces Oxidative Stress-Mediated DNA Damage and Cell Cycle Arrest, and Causes Programmed Cell Death in Anaplastic Thyroid Cancer Cells.
    Xu Q; Mackay RP; Xiao AY; Copland JA; Weinberger PM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.